WallStreetZenWallStreetZen

NASDAQ: SGMT
Sagimet Biosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SGMT

Based on 6 analysts offering 12 month price targets for Sagimet Biosciences Inc

Min Forecast
$10.71-1.56%
Avg Forecast
$27.95+156.91%
Max Forecast
$56.00+414.71%

Should I buy or sell SGMT stock?

Based on 6 analysts offering ratings for Sagimet Biosciences Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SGMT's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates SGMT as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their SGMT stock forecasts and price targets.

SGMT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-09Find Out Why
lockedlocked$00.00+00.00%2026-09-09
lockedlocked$00.00+00.00%2026-08-25
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-08-12Find Out Why
Guggenheim
Top 2%
99
Strong BuyMaintains$25.00+129.78%2026-04-29

1 of 1

Forecast return on equity

Is SGMT forecast to generate an efficient return?

Company
-25.28%
Industry
20.5%
Market
167.94%
SGMT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SGMT forecast to generate an efficient return on assets?

Company
-24.58%
Industry
23.66%
SGMT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SGMT earnings per share forecast

What is SGMT's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$1.20
Avg 2 year Forecast
-$1.39
Avg 3 year Forecast
-$1.51

SGMT revenue forecast

What is SGMT's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$8.5M
Avg 3 year Forecast
$15.6M

SGMT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SGMT$10.88$27.95+156.91%Strong Buy
PHAT$8.36$18.80+124.88%Buy
MDXG$4.57$7.33+60.46%Strong Buy
VSTM$7.32$13.83+88.98%Strong Buy
DBVT$11.85$53.00+347.26%Strong Buy
View Top Biotech Stocks

Sagimet Biosciences Stock Forecast FAQ

Is Sagimet Biosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: SGMT) stock is to Strong Buy SGMT stock.

Out of 6 analysts, 4 (66.67%) are recommending SGMT as a Strong Buy, 2 (33.33%) are recommending SGMT as a Buy, 0 (0%) are recommending SGMT as a Hold, 0 (0%) are recommending SGMT as a Sell, and 0 (0%) are recommending SGMT as a Strong Sell.

If you're new to stock investing, here's how to buy Sagimet Biosciences stock.

What is SGMT's earnings growth forecast for 2026-2028?

(NASDAQ: SGMT) Sagimet Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.83%.

Sagimet Biosciences's earnings in 2026 is -$47,079,000.On average, 13 Wall Street analysts forecast SGMT's earnings for 2026 to be -$74,497,146, with the lowest SGMT earnings forecast at -$90,154,910, and the highest SGMT earnings forecast at -$62,655,922. On average, 13 Wall Street analysts forecast SGMT's earnings for 2027 to be -$86,630,515, with the lowest SGMT earnings forecast at -$112,693,638, and the highest SGMT earnings forecast at -$37,854,620.

In 2028, SGMT is forecast to generate -$94,089,553 in earnings, with the lowest earnings forecast at -$135,232,365 and the highest earnings forecast at -$55,476,598.

What is SGMT's revenue growth forecast for 2026-2028?

(NASDAQ: SGMT) Sagimet Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.23%.

Sagimet Biosciences's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast SGMT's revenue for 2026 to be $0, with the lowest SGMT revenue forecast at $0, and the highest SGMT revenue forecast at $0. On average, 13 Wall Street analysts forecast SGMT's revenue for 2027 to be $530,772,738, with the lowest SGMT revenue forecast at $0, and the highest SGMT revenue forecast at $4,526,890,381.

In 2028, SGMT is forecast to generate $966,567,054 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $5,938,637,708.

What is SGMT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SGMT) forecast ROA is -24.58%, which is lower than the forecast US Biotechnology industry average of 23.66%.

What is SGMT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year SGMT price target, the average SGMT price target is $27.95, with the highest SGMT stock price forecast at $56.00 and the lowest SGMT stock price forecast at $10.71.

On average, Wall Street analysts predict that Sagimet Biosciences's share price could reach $27.95 by Sep 9, 2027. The average Sagimet Biosciences stock price prediction forecasts a potential upside of 156.91% from the current SGMT share price of $10.88.

What is SGMT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SGMT) Sagimet Biosciences's current Earnings Per Share (EPS) is -$1.29. On average, analysts forecast that SGMT's EPS will be -$1.20 for 2026, with the lowest EPS forecast at -$1.45, and the highest EPS forecast at -$1.01. On average, analysts forecast that SGMT's EPS will be -$1.39 for 2027, with the lowest EPS forecast at -$1.81, and the highest EPS forecast at -$0.61. In 2028, SGMT's EPS is forecast to hit -$1.51 (min: -$2.18, max: -$0.89).

What is SGMT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SGMT) forecast ROE is -25.28%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.